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Abstract
Background: Experimental results from studies with inbred mice and their syngeneic tumors
indicated that the inoculation of semi-allogeneic cell hybrids (derived from the fusion between
syngeneic tumor cells and an allogeneic cell line) protects the animal host from a subsequent lethal
challenge with unmodified syngeneic tumor cells.
Methods: Semi-allogeneic somatic cell hybrids were generated by the fusion of EL-4 T lymphoma
cells (H-2b) and BALB/c-derived renal adenocarcinoma RAG cells (H-2d). Cell hybrids were injected
intra-peritoneally (i.p.) in C57BL/6 mice (H-2b) before challenging the mice with a tumorigenic dose
of EL-4 cells.
Results: Semi-allogeneic tumor cell hybrids could not form a tumor in the animal host because
they expressed allogeneic determinants (H-2d) and were rejected as a transplant. However, they
conferred protection against a tumorigenic challenge of EL-4 cells compared to control mice that
were mock-vaccinated with i.p.-injected phosphate-buffered saline (PBS) and in which EL-4
lymphomas grew rapidly to a large size in the peritoneal cavity. Screening of spleen-derived RNA
by means of focused microarray technology revealed up-regulation of genes involved in the Th-1-
type immune response and in the activation of dendritic antigen-presenting cells (APC).
Conclusion: The results of our studies are entirely consistent with the concept that CD80- and
CD86-expressing APC play a central role in mediating the immune protection induced by semi-
allogeneic vaccines by activating a Th-1 response and instructing T cells responsible for killing
autologous tumor cells.
Background
The capacity of T cells to recognize allogeneic MHC mole-
cules as intact structures on the surface of foreign cells is
called direct T-cell allorecognition and is responsible for
the powerful immune reactions associated with transplant
rejection, a phenomenon called "alloagression". To a
large extent this is due to the ability of allogeneic stimula-
tion to mobilize up to 10% of all T lymphocytes, com-
pared with a precursor T-cell frequency of between 10-4
and 10-5 for most common antigens. At the same time,
each of the lymphocytes activated through direct allorec-
ognition will also recognize a specific antigenic peptide
presented in the context of a self major histocompatibility
complex (MHC) molecule (MHC restriction). Cross-reac-
tivity between alloantigens and self MHC-restricted anti-
gens can be harnessed to target tumor antigens [1].
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Experimental results from studies with inbred mice and
their syngeneic tumors indicated that the inoculation of
semi-allogeneic cell hybrids (derived from the fusion
between syngeneic tumor cells and an allogeneic cell line)
protects the animal host from a subsequent lethal chal-
lenge with unmodified syngeneic tumor cells [2,3]. Later
studies confirmed the validity of these observations by
showing that the adoptive transfer of immunity induced
by semi-allogeneic tumor cells required T lymphocytes
and that the enhanced immunity was not due simply to
an allogeneic effect. In fact, co-administration (injection)
into experimental mice of allogeneic cells together with
irradiated autologous tumor cells (i.e., without fusion)
did not fully protect them from a subsequent challenge
with autologous tumor cells, supporting the conclusion
that, in order to achieve maximum anti-tumor protection,
the tumor-associated antigen and the alloantigen needed
to be on the same cell [4-8].
We reported on the use of semi-allogeneic vaccines as
stimulators of HIV-envelope-specific cytotoxic T lym-
phocytes (CTL) and we proposed that semi-allogeneic cell
hybrids functionally mimic APC by concomitantly stimu-
lating alloantigen-specific T helper cells via allogeneic
MHC, and antigen-specific CTL precursors via antigen
presentation through self-MHC [9]. We also proposed
that the Th-1 cytokine response, induced through alloan-
tigen-specific help, activates more efficiently antigen-spe-
cific CTL and that the cytokine-rich microenvironment of
allograft rejection is crucial to attracting dendritic APC.
Recognition of tumor antigens, generally weakly immu-
nogenic, can be enhanced greatly by semi-allogeneic vac-
cines. Consistent with this possibility is the
demonstration that vaccination of mice with allogeneic
fibroblasts transfected with DNA from mouse melanoma
cells and expressing a single MHC class I syngeneic deter-
minant, was capable of protecting mice against a tumori-
genic challenge with syngeneic melanoma cells [10].
Similarly, the immunogenic properties of tumor cells
expressing transfected allogeneic determinants are con-
sistent with this interpretation [11,12].
Although the immunogenic properties of somatic cell
hybrids made with dendritic cells have been the object of
intense study [13-15], it is important to realize that gener-
ation of semi-allogeneic dendritic cell vaccines is very
labor-intensive and difficult to implement in a clinical set-
ting. The studies described in this report indicate that
effective semi-allogeneic vaccines do not require dendritic
cells as a fusion partner, as they specifically activate the
host dendritic cells.
Methods
Cell lines
RAG cells are a non-reverting, 8-azaguanine-resistant
clone of the Renal-2a cell line, originally derived from a
kidney adenocarcinoma of a BALB/c mouse (H-2d haplo-
type). RAG cells are deficient in the X-linked hypoxan-
thine-guanine phosphoribosyl transferase gene (HGPRT-
); therefore, they are killed in culture media containing a
supplement of hypoxanthine, aminopterin, and thymi-
dine (HAT). We confirmed that RAG cells are non-revert-
ing, 8-azaguanine-resistant and HAT-sensitive before
using them in experiments of cell fusion. These cells grow
as a monolayer. EL-4 cells were established from a T-cell
lymphoma induced in a C57BL mouse (H-2b haplotype)
by the chemical carcinogen 9,10-dimethyl-1,2-benzan-
thracene. These cells grow in suspension. RAG and EL-4
cell lines were purchased from the American Type Culture
Collection (ATCC). Both cell lines were propagated in
Dulbecco's modified Eagle's medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), glutamax and
antibiotics (Gibco/Invitrogen).
Derivation of semi-allogeneic hybrids
RAG cell monolayers were trypsinized and the resulting
single-cell suspensions were counted and checked for via-
bility using the Trypan Blue exclusion test. RAG cells in
suspension were mixed with EL-4 cells at a 1 : 3 ratio in
serum-free DMEM, containing 50 μM sodium dodecyl
sulfate (SDS), and spun down at 300×g for 4 min at room
temperature. The mixed cell pellet was then slowly resus-
pended in 1 mL 50% polyethylene glycol (PEG)-1450
(cell-culture grade from the ATCC and diluted in serum-
free DMEM) over a one-minute period while gently stir-
ring. The cell suspension was then slowly diluted over a
two-minute period with DMEM supplemented with 10%
of fetal bovine serum (FBS). After washing twice in DMEM
+ 10% FBS, fused cells were plated in selective medium
(DMEM + 10% FBS and HAT supplement) [16]. Under
these culture conditions only RAG × EL-4 semi-allogeneic
somatic cell hybrids will survive, since RAG cells are killed
and EL-4 cells are lost because they grow in suspension
and do not attach to the plastic substrate like somatic cell
hybrids do.
In vivo animal studies
Pathogen-free C57BL/6 male mice were obtained through
the Jackson Laboratories (Bar Harbor, ME). All mice were
housed in the VA animal facility located on the seventh
floor of the Strom Thurmond Biomedical Research Bldg.
Ten-week-old C57BL/6 male mice were injected intraperi-
toneally (i.p.) with 1 × 106 RAG × EL-4 semi-allogeneic
somatic cell hybrids in 0.5 mL phosphate-buffered saline
(PBS). As a control, age-matched mice were either mock-
vaccinated i.p. with 0.5 mL PBS or injected i.p. with 1 ×
106 RAG cells in 0.5 mL PBS. In separate experiments uti-Journal of Translational Medicine 2007, 5:39 http://www.translational-medicine.com/content/5/1/39
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lizing 1 × 106 EL-4 cells as an antigen, with or without 1 ×
106 RAG cells, in 0.5 mL PBS, all cells used as vaccines
were lethally irradiated with 30 Gy (3,000 rad) in a 137Cs
irradiator. Three weeks after vaccination or mock-vaccina-
tion each mouse was challenged by i.p. injection with
either 2 × 104 or 3 × 104 EL-4 lymphoma cells in 0.5 mL
PBS. Mice were then monitored very closely for growth of
i.p. tumors and sacrificed when the abdomen became
clearly extended, generally within three weeks. Necropsy
was performed on each animal and EL-4 abdominal
tumors were carefully dissected and weighed out. Animal
studies were conducted according to internationally rec-
ognized ethical guidelines and under the full approval of
the Charleston VA Medical Center Institutional Animal
Care & Use Committee (IACUC) (protocol ACORP#346).
Histology
Tumor tissue specimens were fixed in 4% paraformalde-
hyde (PFA) in PBS for 1–2 days, before being transferred
to 30% sucrose in 4%PFA solution until the tissue sam-
ples sank to the bottom of the tube. Specimens were then
placed into labeled plastic molds, covered with OCT
(Optimal Cutting Temperature), and frozen by contact
with dry ice. Frozen sections (5 μm thick) were placed on
to slides coated with a solution containing 1% gelatin and
0.2% chromium poatassium sulfate; slides were dried
overnight. The following day tissue sections on slides were
stained with Hematoxylin & Eosin and a coverslip was
mounted (Permount) on each slide.
Statistical considerations
Data were analyzed by one-way analysis of variance for
analyses of statistical significance, with p < 0.05 indicating
statistical significance, using GraphPad Prism software
program.
Studies with focused microarrays
Total RNAs were isolated from spleens of untreated mice,
mock-vaccinated and vaccinated mice, respectively.
Spleens collected from mice vaccinated with semi-alloge-
neic cell hybrids were from animals that had no tumor.
These pooled RNAs were subjected to focused microarray
analyses of murine Th1-Th2-Th3 immune function
(Superarray Bioscience Corp., cat.# OMM-034).
Subsequently, RNAs were also analyzed using dendritic
cell (DC)-specific microarrays (Superarray Bioscience
Corp., cat.# OMM-406). All data from these experiments
were normalized using minimum value background sub-
traction and expression of housekeeping genes, before
being compared. Minimum value is the lowest density
reading of a spot on the array. It is defined, by default, as
the background and it is subtracted from the intensity
value for each spot on the array. Scatter plot comparisons
were performed in a blinded fashion by the microarray
manufacturer (Superarray Bioscience Corp.), and
included only genes that showed either up-regulation or
down-regulation by 1.5 fold or more.
Results
In vivo animal studies with EL-4 T lymphoma cells
These experiments were carried out to investigate whether
RAG × EL-4 semi-allogeneic somatic cell hybrids were able
to protect C57BL/6 mice against a tumorigenic challenge
with EL-4 cells. Ten-week-old C57BL/6 male mice were
injected intraperitoneally (i.p.) with 1 × 106 RAG × EL-4
semi-allogeneic somatic cell hybrids in 0.5 mL phosphate-
buffered saline (PBS). As a control, age-matched mice
were mock-vaccinated i.p. with 0.5 mL PBS. Three weeks
after vaccination or mock-vaccination each mouse was
challenged by i.p. injection with either 2 × 104 or 3 × 104
EL-4 lymphoma cells in 0.5 mL PBS. Mice were then mon-
itored very closely for growth of i.p. tumors and sacrificed
when the abdomen became clearly extended, generally
within three weeks. Necropsy was performed on each ani-
mal and EL-4 abdominal tumors were carefully dissected
and weighed out. Figure 1 shows the result of these exper-
iments.
All mock-vaccinated mice challenged with EL-4 cells
developed large tumors. The mean tumor size of mice
injected i.p. with 2 × 104 cells was 3.9 grams and the mean
Anti-tumor protection conferred by semi-allogeneic vaccines Figure 1
Anti-tumor protection conferred by semi-allogeneic vac-
cines. The bar graph shows the average tumor weight per 
mouse and the standard deviation. Differences in tumor 
weight between mock-vaccinated mice (PBS) and mice vacci-
nated with semi-allogeneic cell hybrids (Vac) were statisti-
cally significant for both challenges: p-values were < 0.0001 
and 0.0017 for the 2 × 104 and the 3 × 104 EL-4 lymphoma 
cells challenge, respectively.
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tumor size of mice injected i.p. with 3 × 104 cells was 4.3
grams. In contrast, three of five vaccinated mice that were
challenged i.p. with 2 × 104 EL-4 cells showed no evidence
of abdominal tumor growth at time of sacrifice and the
mean tumor size in this group of mice was 0.2 grams. Sim-
ilarly, one of five vaccinated mice that were challenged i.p.
with 3 × 104 EL-4 cells showed no evidence of abdominal
tumor growth at time of sacrifice and the mean tumor size
in this group of mice was 1.4 grams. Differences in tumor
size between vaccinated and mock-vaccinated mice were
statistically significant for both challenges (p-values were
< 0.0001 and 0.0017 for the 2 × 104 and the 3 × 104 EL-4
lymphoma cells challenge, respectively). Histological
examination of tumors from mice mock-vaccinated with
PBS compared to those from mice vaccinated with RAG ×
EL-4 semi-allogeneic somatic cell hybrids showed no
notable difference (Figure 2).
A second set of animal experiments was performed to
investigate whether the anti-tumor protection was the
result of an allogeneic effect. Three groups of mice were
utilized: 1) mock-vaccinated with 0.5 mL PBS alone
(Non-Imm); 2) vaccinated with 1 × 106 RAG cells in 0.5
mL PBS (Allo); 3) vaccinated with 1 × 106 RAG × EL-4
semi-allogeneic somatic cell hybrids in 0.5 mL PBS (Semi-
Allo). After three weeks each mouse was challenged by i.p.
injection with 2 × 104 EL-4 lymphoma cells in 0.5 mL PBS
and mock-vaccinated mice showed an extended abdomen
because of i.p. tumor growth within three weeks from the
day of challenge. At the time of sacrifice, all mock-vacci-
nated mice challenged with EL-4 cells had developed large
tumors and the mean tumor size was 5.1 grams; also, four
of five mice vaccinated with allogeneic RAG cells and chal-
lenged with EL-4 cells had i.p. tumors (mean tumor size:
2.0 grams). In contrast, four of ten mice vaccinated with
RAG × EL-4 semi-allogeneic somatic cell hybrids and sub-
sequently challenged i.p. with 2 × 104 EL-4 cells showed
no evidence of abdominal tumor growth at time of sacri-
fice and mean tumor size in this group of mice was 0.7
grams (Figure 3). The results of these animal studies
clearly indicate that, although the i.p. injection of alloge-
neic cells (RAG) conferred some degree of anti-tumor pro-
tection compared to mock-vaccinated mice, semi-
allogeneic vaccines were significantly better at inducing
specific anti-tumor protection.
A third set of animal experiments was performed to inves-
tigate whether i.p. vaccination with 1 × 106 irradiated EL-
4 cells plus 1 × 106 irradiated RAG cells would protect the
mice from a subsequent challenge with 2 × 104 EL-4 live
cells. Lethal irradiation (30 Gy in a 137Cs irradiator) was
needed to prevent the growth of live EL-4 cells as a tumor.
We also wanted to compare the anti-tumor protection
resulting from co-injection of EL-4 and RAG irradiated
cells with the anti-tumor protection observed following
vaccination with 1 × 106 RAG × EL-4 irradiated semi-allo-
geneic somatic cell hybrids. For these experiments five
groups of mice were injected i.p. as follows: 1) mock-vac-
cination with 0.5 mL PBS/mouse; 2) vaccination with 1 ×
106 irradiated EL-4 cells in 0.5 mL PBS/mouse; 3) vaccina-
tion with 1 × 106 irradiated RAG cells in 0.5 mL PBS/
mouse; 4) vaccination with 1 × 106 irradiated EL-4 cells
plus 1 × 106 irradiated RAG cells in 0.5 mL PBS/mouse; 5)
vaccination with 1 × 106 RAG × EL-4 irradiated semi-allo-
geneic somatic cell hybrids in 0.5 mL PBS/mouse. After
three weeks each mouse was challenged by i.p. injection
with 2 × 104 live EL-4 lymphoma cells in 0.5 mL PBS.
Nineteen days after challenge, all mice mock-vaccinated
with PBS and all mice vaccinated with irradiated EL-4 cells
had developed tumors, and most of the mice vaccinated
with irradiated RAG cells or with irradiated EL-4 cells plus
irradiated RAG cells had also developed tumors. In con-
trast, none of the mice vaccinated with RAG × EL-4 irradi-
ated semi-allogeneic somatic cell hybrids showed any
signs of tumor growth at day nineteen after challenge (Fig-
ure 4).
Later on some of these mice developed intra-peritoneal
tumors; however, four of ten mice vaccinated with RAG ×
EL-4 irradiated semi-allogeneic somatic cell hybrids
remained tumor-free at five weeks after challenge. Even
though the co-injection of irradiated EL-4 cells and irradi-
ated RAG cells seemed to confer a significant degree of
anti-tumor protection compared to mock-vaccinated
(PBS) mice, these experimental results clearly demon-
strate that, in order to achieve maximum anti-tumor pro-
tection, the tumor-associated antigen and the alloantigen
need to be on the same cell (the hybrid).
Studies with focused microarrays
To investigate the biological and molecular requirements
for protective immunity and understand the mechanisms
underlying the specific anti-tumor response induced by
semi-allogeneic vaccines, total RNA was isolated from
spleens of untreated mice, mock-vaccinated and vacci-
nated mice and analyzed by microarray technology.
Spleen RNA from both experiments was subjected to
focused microarray analyses of murine Th1-Th2-Th3
immune function (Superarray Bioscience Corp., cat.#
OMM-034). The results obtained with both sets of sam-
ples showed consistent over-expression of select genes
associated with Th-1 immune function in the spleen of
mice vaccinated with semi-allogeneic somatic cell hybrids
(immune mice). In contrast, the spleen from mock-vacci-
nated (non-immune) mice revealed over-expression of
Th-2 immune functions. The spleen of mice immunized
with allogeneic vaccine (allo-immune mice) over-
expressed some – but not all – of the transcripts that were
elevated in the spleen of immune mice. The results ofJournal of Translational Medicine 2007, 5:39 http://www.translational-medicine.com/content/5/1/39
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these microarray studies are summarized in Tables 1 and
2.
Mice immunized with allogeneic vaccine (allo-immune
mice) shared with the immune mice the over-expression
of only some of the genes (C2ta, Stat1, FASLG, and
HAVCR2) listed in Table 1, indicating that the immune
mechanisms triggered by the allogeneic response do not
account for the molecular complexity and specificity of
the anti-tumor immune protection conferred by semi-all-
ogeneic vaccination.
These observations prompted us to analyze the same
RNAs using dendritic cell (DC)-specific microarrays
(Superarray Bioscience Corp., cat.# OMM-406). When
compared to mock-vaccinated (non-immune) and to all-
ogeneic cell-vaccinated (allo-immune) mice, the spleen of
immune, tumor-free mice (vaccinated with semi-alloge-
neic somatic cell hybrids) expressed significantly higher
levels of the following notable genes (in addition to those
listed in Table 1): CD209a (DC-SIGN), CD28, CD83, FAS,
Flt3L, H2-DMa, ICOSL (B7-H2), ITGAX (CD11C), LTA,
Hematoxylin & Eosin staining of tissue sections from EL-4-derived tumors Figure 2
Hematoxylin & Eosin staining of tissue sections from EL-4-derived tumors. Panels A and B show low and high magnification 
(with scale bars) of a typical EL-4 tumor from a mouse mock-vaccinated with PBS three weeks before challenge. Panels C and 
D show low and high magnification (with scale bars) of EL-4 tumor sections from a mouse vaccinated with RAG × EL-4 semi-
allogeneic hybrids three weeks before challenge. Note, that both tumors appear to be poorly differentiated (anaplastic), and 
that there are no morphologic features that distinguish them.
A                B 
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NFKB, and XCL1 (ATAC). These results are summarized in
Table 3.
The results of these microarray experiments indicate that
semi-allogeneic vaccines trigger the recruitment and acti-
vation of helper T lymphocytes and dendritic APC; in
turn, these cells establish a strong Th-1 response, which
leads to the activation of CTL to specifically recognize and
kill their target tumor cells.
Discussion
These studies were undertaken to further our understand-
ing of the mechanisms underlying the specific anti-tumor
response induced by semi-allogeneic vaccines. Specifi-
cally, the results of our microarray studies are entirely con-
sistent with the concept that CD80- and CD86-expressing
APC play a central role in mediating the immune protec-
tion induced by semi-allogeneic vaccines by activating a
strong Th-1 response and instructing T cells responsible
for killing autologous tumor cells. These results are also
consistent with a recent report on molecular signatures
induced by interleukin (IL)-2 on human peripheral blood
mononuclear cells [17].
Table 1: Genes over-expressed in spleen of Immune Mice. Values within square brackets [] represent the fold increase in the expression 
of each gene by mice vaccinated with semi-allogeneic vaccines compared to mice mock-vaccinated with PBS.
CD80 (B7-1) [1.9]
CD86 (B7-2) [1.8]
Cell surface molecules expressed by activated APC that provide a co-stimulatory signal to T cells by interacting with CD28
C2ta [2.0] Enhancer of T-cell activation and proliferation and suppressor of Th2-type cytokine expression
STAT1 [2.0] Signal transducer and activator of transcription 1, activated by various ligands including interferon α (IFN- α) and IFN-γ
STAT4 [2.0] Another member of the Stat family of transcription factors that is essential for mediating responses to IL-12 in lymphocytes 
and for regulating the differentiation of T helper cells
CD40 [2.0] A co-stimulatory molecule expressed on the surface of B lymphocytes, dendritic cells, and follicular dendritic cells
FASLG [1.8] Critical for triggering apoptosis of some types of cells following interaction with FAS
HAVCR2 [2.5] Hepatitis A virus cellular receptor 2, over-expressed by activated CD4 Th1 cells and CD11b+ macrophages
Anti-tumor protection conferred by semi-allogeneic vs. allo- geneic vaccines Figure 3
Anti-tumor protection conferred by semi-allogeneic vs. allo-
geneic vaccines. The bar graph shows the average tumor 
weight per mouse and the standard deviation. Differences in 
tumor weight between mock-vaccinated mice (Non-Imm) 
and mice vaccinated with semi-allogeneic cell hybrids (Semi-
Allo) were the most significant (p-value < 0.0001). Also sig-
nificant were differences in tumor weight between mock-vac-
cinated mice and mice vaccinated with allogeneic RAG cells 
(p-value = 0.0183), as well as between mice injected with 
semi-allogeneic vs. allogeneic vaccines (p-value = 0.0458).
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Anti-tumor protection conferred by injection of irradiated  semi-allogeneic vaccines compared to co-injection of irradi- ated EL-4 cells plus irradiated RAG cells Figure 4
Anti-tumor protection conferred by injection of irradiated 
semi-allogeneic vaccines compared to co-injection of irradi-
ated EL-4 cells plus irradiated RAG cells. The bar graph 
shows the average tumor weight per mouse and the standard 
deviation for each group of mice. The five groups were 
immunized as follows: 1) mock-vaccination (PBS); 2) 1 × 106 
irradiated EL-4 cells (iEL-4); 3) 1 × 106 irradiated RAG cells 
(iRAG); 4) 1 × 106 irradiated EL-4 cells co-injected with 1 × 
106 irradiated RAG cells (iEL-4 + iRAG); 5) 1 × 106 irradiated 
EL-4 × RAG semi-allogeneic somatic cell hybrids (iEL-4 × 
RAG). Using mock-vaccination (PBS) as a control, the p-val-
ues were as follows: iEL-4 p-value = 0.5469; iRAG p-value = 
0.3065; iEL-4 + iRAG (co-injection) p-value = 0.0417; and 
iEL-4 × RAG (hybrids) p-value < 0.00001.
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Interest in semi-allogeneic cancer vaccines has been
increasing, as demonstrated by the publication of success-
ful pre-clinical and clinical studies by us [9,16,18,19] and
others [13,20] that validate this approach. Specifically, we
observed that lymphocytes from HLA-A2+ melanoma and
HIV+ patients, stimulated in vitro with HLA-A2-restricted
antigenic peptides in the presence of irradiated semi-allo-
geneic cell hybrids lysed target cells presenting the same
peptide more efficiently than lymphocytes stimulated
with antigenic peptide alone [9,19]. We were allowed by
the FDA, under BB-IND 6266, to conduct two Phase I
studies in patients with disseminated melanoma [16] and
metastatic adenocarcinoma [18]. We determined that
treatment of cancer patients with irradiated semi-alloge-
neic vaccines is associated with minimal or no toxicity and
can induce a specific anti-tumor immune response, meas-
ured by a positive delayed-type hypersensitivity (DTH) to
irradiated autologous tumor cells injected intra-dermally.
In one melanoma patient with stage III disease and treated
with semi-allogeneic vaccine, we observed the reduction
in size of two lymph nodes with melanoma cells and the
patient is still free of disease almost ten years after vacci-
nation.
However, in spite of some encouraging outcomes, the
results of clinical studies employing semi-allogeneic vac-
cines as immunotherapeutics against a variety of neopla-
sias have not matched the expectations raised from the
striking anti-tumor protection conferred by semi-alloge-
neic vaccines in a variety of animal models. It is tempting
to speculate that the well-documented success of semi-all-
ogeneic vaccines in animal models is due to the high prev-
alence of cancer stem cells [21] in the experimental
tumors utilized for these studies. We observed that 2 × 104
EL-4 T lymphoma cells injected i.p. into C57BL/6 mice
give rise to a 5 gram tumor in three weeks or less, suggest-
ing that a large percentage of these cells fulfill the opera-
tional criteria for cancer stem cells.
There is a growing consensus that malignancies remain
incurable unless their cancer stem cells are eliminated
[21]. It is reasonable to explore the concept that clinically
effective semi-allogeneic vaccines need to be generated
from patient-derived cancer stem cells fused with appro-
priate allogeneic cells, because only cancer stem cells will
express the pathogenetic and antigenic determinants that
are critical to a successful immunotherapy. Cancer stem
cells are responsible for the persistence/recurrence of
tumors; these cells tend to be drug-resistant and are
responsible for the dissemination and metastatic growth
of tumors. Cancer stem cells must be killed to achieve
clinical responses that are both complete and durable.
Semi-allogeneic vaccines derived from the fusion of can-
cer stem cells and an appropriate allogeneic cell partner
would provide an additional treatment for cancer
patients, especially before their disease reaches the late
Table 3: DC-specific genes that are over-expressed in spleen of Immune Mice. Values within square brackets [] represent the fold 
increase in the expression of each gene by mice vaccinated with semi-allogeneic vaccines compared to mice mock-vaccinated with 
PBS. These over-expressed genes are in addition to those listed in Table 1.
DC-SIGN [4.0] (CD209a) A cell surface C-type lectin expressed by dendritic cells that mediates antigen capture for processing and 
presentation
CD28 [1.6] T cell-specific receptor for CD80 and CD86
CD83 [1.9] The most reliable activation marker for mature dendritic cells
FAS [2.1] The apoptosis-mediating membrane-associated polypeptide that belongs to the tumor necrosis factor receptor 
superfamily
Flt3L [1.7] A ligand that expands type-1 dendritic cells and enhances the immune response by augmenting T-cell activity
H2-DMa [2.0] Involved in antigen processing and presentation of exogenous peptide antigens via MHC class II
ICOSL [2.6] (B7-H2) Is a ligand for T cell-specific, cell surface receptor ICOS and acts as a co-stimulatory signal for T-cell proliferation and 
cytokine secretion
CD11c [1.7] (ITGAX) Expressed by dendritic cells that tend to generate Th1 effectors
LTA [1.7] (TNF-β) Lymphotoxin α or tumor necrosis factor β
NFKB [1.5] A transcription factor required for STAT-4 expression during dendritic cell maturation
XCL1 [2.5] (ATAC) An activation-induced, T cell-derived and chemokine-related type 1 cytokine, that cooperates with interferon (IFN)-
γ in the up-regulation of CD40 and interleukin (IL)-12 expression
Table 2: Genes over-expressed in spleen of Non-Immune Mice. Values within square brackets [] represent the fold increase in the 
expression of each gene by mice mock-vaccinated with PBS compared to mice vaccinated with semi-allogeneic vaccines.
LAT [2.9] Linker for activation of T cells, involved in T-cell receptor (TCR)-initiated, T cell-specific signaling events and possibly associated 
with over- stimulation and apoptosis of T cells
GATA3 [2.5] GATA binding protein 3, a transcription factor that favors expression of Th2-type cytokines
SOCS3 [1.5] Suppressor of cytokine signaling 3, is a negative regulator of cytokine signaling
Gfi1 [3.8] Growth factor independent 1, a transcriptional repressor essential during myeloid differentiation (Gfi1-/- mice exhibit diminished 
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and often irreversible stage. Therefore, it is virtually cer-
tain that the field of immunotherapy will benefit consid-
erably from the rapidly increasing body of knowledge
being generated in the emerging field of human cancer
stem cell research.
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